# Hypoxia-driven remodeling of SELENOP+ macrophages shapes T cell dynamics and promotes ovarian cancer metastasis

**Authors:** Qing Liu, Chenzhao Feng, Tianhao Wu, Siyang Zhang, Xinyi Wang, Qian Zhao, Xueying Song, Shuangyan Liu, Linru Quan, Yuli Zhang, Shimin Zhang, Bin Yang, Jixin Li, Gang Chen, Xuanzhang Huang, Chaoyang Sun, Xin Zhou

PMC · DOI: 10.1038/s41467-025-67859-2 · 2026-01-12

## TL;DR

This study explores how SELENOP+ macrophages in the tumor environment influence T cell activity and promote the spread of ovarian cancer.

## Contribution

The study identifies SELENOP+ macrophages as key drivers of T cell dynamics and metastasis in ovarian cancer.

## Key findings

- SELENOP+ macrophages activate CD8+ T cells via selenoprotein P in vitro and in vivo.
- Anti-VEGFA intervention increases SELENOP+ macrophages and CD8+ T cell cytotoxicity in vivo.
- Hypoxia-driven VEGFA-EPHB2 signaling promotes macrophage transitions and tumor metastasis.

## Abstract

High-grade serous ovarian cancer (HGSOC) is characterized by extensive transcoelomic dissemination and the accumulation of ascites. However, how site-specific tumor microenvironment (TME) drives progression remains unknown. Here we show the co-occurrence and spatial co-localization of SELENOP+ macrophages and precursor exhausted CD8+ T cells and demonstrate that SELENOP+ macrophages activate T cells via selenoprotein P in vitro and in vivo. We further identify a dynamic transition in the SELENOP+/SPP1+ macrophage populations as tumor metastasis, driven by increased hypoxia malignant epithelial cells through VEGFA-EPHB2 signaling. We also reveal that anti-VEGFA intervention controls ovarian tumor growth by increasing SELENOP+ macrophages and cytotoxicity of CD8+ T cells in vivo. Taken together, these findings spotlight the role of tumor-induced TME remodeling in subverting immune-mediated tumor control and thus facilitating HGSOC metastasis in females. Collectively, our results provide a foundation for the development of targeted therapeutic interventions aimed at impeding HGSOC metastatic trajectory.

How site-specific tumor microenvironment (TME) drives the metastasis of high-grade serous ovarian cancer (HGSOC) remains unclear. Here, the authors employ an integrated single cell multi-omics approach to map the spatiotemporal heterogeneity of HGSOC metastasis TME and identify an interaction network within the TME driven by SELENOP+ macrophages and pre-exhausted CD8+ T cells.

## Linked entities

- **Genes:** SELENOP (selenoprotein P) [NCBI Gene 6414], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422], EPHB2 (EPH receptor B2) [NCBI Gene 2048]
- **Proteins:** SPP1 (secreted phosphoprotein 1)
- **Diseases:** ovarian cancer (MONDO:0005140)

## Full-text entities

- **Genes:** IRF8 (interferon regulatory factor 8) [NCBI Gene 3394] {aka H-ICSBP, ICSBP, ICSBP1, IMD32A, IMD32B, IRF-8}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 397087] {aka Opn}, HMGA2 (high mobility group AT-hook 2) [NCBI Gene 8091] {aka BABL, HMGI-C, HMGIC, LIPO, SRS5, STQTL9}, CXCL13 (C-X-C motif chemokine ligand 13) [NCBI Gene 10563] {aka ANGIE, ANGIE2, BCA-1, BCA1, BLC, BLR1L}, Adgre1 (adhesion G protein-coupled receptor E1) [NCBI Gene 13733] {aka DD7A5-7, EGF-TM7, Emr1, F4/80, Gpf480, Ly71}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, EOMES (eomesodermin) [NCBI Gene 8320] {aka TBR2}, MYO1A (myosin IA) [NCBI Gene 4640] {aka BBMI, DFNA48, DIAR15, MIHC, MYHL}, Cd68 (CD68 antigen) [NCBI Gene 12514] {aka Lamp4, Scard1, gp110}, LIM2 (lens intrinsic membrane protein 2) [NCBI Gene 3982] {aka CTRCT19, MP17, MP19}, Gzmb (granzyme B) [NCBI Gene 14939] {aka CCP-1/C11, CCP1, Ctla-1, Ctla1, GZB}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, SELENOP (selenoprotein P) [NCBI Gene 100037964] {aka SEPP1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, Spp1 (secreted phosphoprotein 1) [NCBI Gene 20750] {aka 2AR, Apl-1, BNSP, BSPI, Bsp, ETA-1}, GZMH (granzyme H (cathepsin G-like 2, protein h-CCPX)) [NCBI Gene 100152450], FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, TCF7 (transcription factor 7) [NCBI Gene 6932] {aka TCF-1}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, Hif1a (hypoxia inducible factor 1, alpha subunit) [NCBI Gene 15251] {aka HIF-1-alpha, HIF1-alpha, HIF1alpha, MOP1, bHLHe78}, MYB (MYB proto-oncogene, transcription factor) [NCBI Gene 4602] {aka Cmyb, c-myb, c-myb_CDS, efg}, EPHB2 (EPH receptor B2) [NCBI Gene 2048] {aka BDPLT22, CAPB, DRT, EK5, EPHT3, ERK}, LAYN (layilin) [NCBI Gene 143903], GZMH (granzyme H) [NCBI Gene 2999] {aka CCP-X, CGL-2, CSP-C, CTLA1, CTSGL2}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, EPHA1 (EPH receptor A1) [NCBI Gene 2041] {aka EPH, EPHT, EPHT1}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, MIF (macrophage migration inhibitory factor) [NCBI Gene 4282] {aka GIF, GLIF, MMIF}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, Dnase1 (deoxyribonuclease I) [NCBI Gene 13419] {aka DNaseI, Dnl1}, TRDV2 (T cell receptor delta variable 2) [NCBI Gene 28517] {aka hDV102S1}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}, FTL (ferritin light chain) [NCBI Gene 2512] {aka FTL1, LFTD, NBIA3}, SLC4A10 (solute carrier family 4 member 10) [NCBI Gene 57282] {aka NBCn2, NCBE}, HAVCR2 (hepatitis A virus cellular receptor 2) [NCBI Gene 84868] {aka CD366, HAVcr-2, KIM-3, SPTCL, TIM3, TIMD-3}, FGF10 (fibroblast growth factor 10) [NCBI Gene 2255] {aka LADD3}, LAT (linker for activation of T cells) [NCBI Gene 27040] {aka IMD52, LAT1, pp36}, TIGIT (T cell immunoreceptor with Ig and ITIM domains) [NCBI Gene 201633] {aka VSIG9, VSTM3, WUCAM}, Pdcd1 (programmed cell death 1) [NCBI Gene 18566] {aka Ly101, PD-1, Pdc1}, GNLY (granulysin) [NCBI Gene 10578] {aka D2S69E, LAG-2, LAG2, NKG5, TLA519}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, GZMA (granzyme A) [NCBI Gene 3001] {aka CTLA3, HFSP}, Selenop (selenoprotein P) [NCBI Gene 20363] {aka D15Ucla1, Se-P, Sepp1, selp}, SELENOP (selenoprotein P) [NCBI Gene 6414] {aka SELP, SEPP, SEPP1, SeP}, TPSP1 (tryptase pseudogene 1) [NCBI Gene 100129339] {aka MP-2}, CEBPA (CCAAT enhancer binding protein alpha) [NCBI Gene 1050] {aka C/EBP-alpha, CEBP}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, MX1 (MX dynamin like GTPase 1) [NCBI Gene 4599] {aka IFI-78K, IFI78, MX, MxA, lncMX1-215}, LAG3 (lymphocyte activating 3) [NCBI Gene 3902] {aka CD223}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}
- **Diseases:** Hypoxia (MESH:D000860), metastases (MESH:D009362), inflammatory (MESH:D007249), adnexal tumor lesion (MESH:D000291), mEpi (MESH:D002277), NMF (MESH:C538347), metastatic (MESH:D000092182), ovarian lesions (MESH:D010049), TAM (MESH:D020914), omental lesions (MESH:D015436), TAMs (MESH:D000072716), uterine fibroids (MESH:D007889), Ascites (MESH:D001201), gynecological malignancy (MESH:D005833), adnexal tumor (MESH:D000292), infection (MESH:D007239), CNV (OMIM:610141), EAT (MESH:D062706), T lymphoma (MESH:D008223), Cytotoxic (MESH:D064420), Ovarian cancer (MESH:D010051), Malignant (MESH:D009369), peritoneal (MESH:D010538), tumorigenic (MESH:D002471), hypoxic (MESH:D002534), lung cancer (MESH:D008175)
- **Chemicals:** N-acetyl-L-cysteine (MESH:D000111), O2 (MESH:D010100), Penicillin (MESH:D010406), Phosphate (MESH:D010710), streptomycin (MESH:D013307), propidium iodide (MESH:D011419), HEPES (MESH:D006531), Y27632 (MESH:C108830), Saline (MESH:D012965), isoflurane (MESH:D007530), acridine orange (MESH:D000165), paraffin (MESH:D010232), CO2 (MESH:D002245), Sec (MESH:D017279), Selenium (MESH:D012643), forskolin (MESH:D005576), platinum (MESH:D010984), DAPI (MESH:C007293), nicotinamide (MESH:D009536), OCT (MESH:C051883), PI (MESH:D010716), PMA (MESH:D013755), bevacizumab (MESH:D000068258), polybrene (MESH:D006583), puromycin (MESH:D011691), -PB-500 (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** OCL3 — Homo sapiens (Human), Ovarian carcinoma, Cancer cell line (CVCL_6702), C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), Jurkat — Homo sapiens (Human), Childhood T acute lymphoblastic leukemia, Cancer cell line (CVCL_0065), COV362 — Homo sapiens (Human), High grade ovarian serous adenocarcinoma, Cancer cell line (CVCL_2420), OVCAR3 — Homo sapiens (Human), High grade ovarian serous adenocarcinoma, Cancer cell line (CVCL_0465), /6J — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_W797), MP6 — Mus musculus (Mouse), Hybridoma (CVCL_A0RL), ID8 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_IU14), M0 — Homo sapiens (Human), Familial hypertrophic cardiomyopathy type 26, Induced pluripotent stem cell (CVCL_A6XE), OCL5 — Homo sapiens (Human), Ovarian clear cell adenocarcinoma, Cancer cell line (CVCL_6701), OT-1 — Homo sapiens (Human), Lung small cell carcinoma, Cancer cell line (CVCL_7018), L-WRN — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_DA06), CAOV3 — Homo sapiens (Human), High grade ovarian serous adenocarcinoma, Cancer cell line (CVCL_0201), M06 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_S857), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12852879/full.md

---
Source: https://tomesphere.com/paper/PMC12852879